A phase II trial for GV in patients with refractory or relapsed osteosarcoma showed that of the 22 patients enrolled, only 1 patient had partial response and 2 had stable disease and reported that there was no correlation between gpNMB expression and GV response [264], indicating that GV did not have substantial clinical efficacy. This evidence concerns the gene GPNMB and osteosarcoma.